Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults
BackgroundMigraine is a neurological condition marked by frequent headaches, which tends to be accompanied by nausea and vomiting in severe instances. Injectable therapies for migraine, such as monoclonal antibodies that target calcitonin gene-related peptide (CGRP), have proven to be effective and...
Saved in:
| Main Authors: | Adarsh Raja, Rabia Asim, Muhammad Hamza Shuja, Sandesh Raja, Tazheen Saleh Muhammad, Simran Bajaj, Abdul Hadi Ansari, Hamza Ali, Iffat Ambreen Magsi, Muhammad Hammad Faridi, Hamza Ali Hasnain Sheikh, Muhammad Junaid Imran, Muhammad Ahmed, Muhammad Sohaib Asghar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-09-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2024.1468961/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corrigendum: Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults
by: Adarsh Raja, et al.
Published: (2025-04-01) -
Clinical Pharmacokinetics of Atogepant in Healthy Japanese and White Adults
by: Ramesh R. Boinpally, et al.
Published: (2025-01-01) -
“The efficacy and safety of Atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials”
by: Ayesha Shaukat, et al.
Published: (2025-08-01) -
GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures
by: Piero Barbanti, et al.
Published: (2025-05-01) -
Small-molecule CGRP antagonist atogepant does not affect cortical spreading depression susceptibility in rats
by: Xuyan Jin, et al.
Published: (2025-08-01)